A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)

NCT Number	NCT07646587
Lead Sponsor	Windward Bio
Conditions	COPD (Chronic Obstructive Pulmonary Disease)
Enrollment	105 participants
Start Date	2026-06-02
Primary Completion	2027-12-17 (estimated)
Study Completion	2028-01-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-22